DD201974A5 - Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin - Google Patents

Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin Download PDF

Info

Publication number: DD201974A5
Authority: DD; German Democratic Republic
Prior art keywords: nifedipine; pharmaceutical preparations; specific surface; surface area; preparations containing
Prior art date: 1980-09-09

Application number

DD81232939A

Other languages

German (de)

English (en)

Inventor

Ahmed Hegasy

Klaus-Dieter Raemsch

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-09-09

Filing date

1981-09-01

Publication date

1983-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6111496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD201974(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1981-09-01 Application filed by Bayer Ag filed Critical Bayer Ag

1983-08-24 Publication of DD201974A5 publication Critical patent/DD201974A5/de

Links

HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 title claims abstract description 40
229960001597 nifedipine Drugs 0.000 title claims abstract description 40
238000002360 preparation method Methods 0.000 title claims abstract description 22
239000007787 solid Substances 0.000 title claims abstract description 14
239000003814 drug Substances 0.000 title description 3
238000004519 manufacturing process Methods 0.000 title description 2
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 8
238000003801 milling Methods 0.000 claims abstract description 6
230000015572 biosynthetic process Effects 0.000 claims abstract description 3
238000007873 sieving Methods 0.000 claims abstract description 3
238000003786 synthesis reaction Methods 0.000 claims abstract description 3
238000007796 conventional method Methods 0.000 claims abstract 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 2
239000013078 crystal Substances 0.000 abstract description 11
239000000203 mixture Substances 0.000 abstract description 10
150000001875 compounds Chemical class 0.000 abstract description 3
239000000126 substance Substances 0.000 abstract description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract 1
239000002775 capsule Substances 0.000 description 7
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
229920002472 Starch Polymers 0.000 description 4
239000013543 active substance Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
206010034972 Photosensitivity reaction Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000036211 photosensitivity Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000004438 BET method Methods 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)

DD81232939A 1980-09-09 1981-09-01 Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin DD201974A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19803033919 DE3033919A1 (de)	1980-09-09	1980-09-09	Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung

Publications (1)

Publication Number	Publication Date
DD201974A5 true DD201974A5 (de)	1983-08-24

Family

ID=6111496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD81232939A DD201974A5 (de)	1980-09-09	1981-09-01	Verfahren zur herstellung von festen arzneizubereitungen enthaltend nifedipin

Country Status (20)

Country	Link
EP (1)	EP0047899B2 (it)
JP (1)	JPS5914446B2 (it)
AR (1)	AR226377A1 (it)
AT (1)	ATE5761T1 (it)
AU (1)	AU558331B2 (it)
CA (1)	CA1180277A (it)
DD (1)	DD201974A5 (it)
DE (2)	DE3033919A1 (it)
DK (1)	DK154326C (it)
FI (1)	FI72648B (it)
GR (1)	GR78237B (it)
HU (1)	HU184879B (it)
IE (1)	IE51549B1 (it)
IL (1)	IL63749A (it)
NO (1)	NO157368B (it)
NZ (1)	NZ198285A (it)
PH (1)	PH24097A (it)
PL (1)	PL232951A1 (it)
PT (1)	PT73603B (it)
ZA (1)	ZA816213B (it)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
JPS5846019A (ja) *	1981-09-14	1983-03-17	Kanebo Ltd	持続性ニフエジピン製剤
DE3222367A1 (de) *	1982-06-15	1983-12-15	Bayer Ag, 5090 Leverkusen	Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung
JPS59101423A (ja) *	1982-12-02	1984-06-12	Takada Seiyaku Kk	新規なニフエジピン固形製剤
US4529733A (en) *	1983-04-06	1985-07-16	Merrell Dow Pharmaceuticals Inc.	Antihypertensive 3-furoyl-1,4-dihydropyridines
DE3318649A1 (de) *	1983-05-21	1984-11-22	Bayer Ag, 5090 Leverkusen	Zweiphasenformulierung
HU198844B (en) *	1984-06-14	1989-12-28	Sandoz Ag	Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
IT1178511B (it) *	1984-09-14	1987-09-09	Pharmatec Spa	Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
IT1187751B (it) *	1985-10-15	1987-12-23	Eurand Spa	Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US5198226A (en) *	1986-01-30	1993-03-30	Syntex (U.S.A.) Inc.	Long acting nicardipine hydrochloride formulation
US4940556A (en) *	1986-01-30	1990-07-10	Syntex (U.S.A.) Inc.	Method of preparing long acting formulation
CH673947A5 (it) *	1986-09-23	1990-04-30	Sandoz Ag
JPS6464659A (en) *	1987-09-03	1989-03-10	Kenbi Kogaku Kenkyusho Kk	Preparation of safe and effective powder formulation
SE8703881D0 (sv) *	1987-10-08	1987-10-08	Haessle Ab	New pharmaceutical preparation
DE3814532A1 (de) *	1988-04-29	1989-11-09	Bayer Ag	Dhp-retard-zubereitung
JPH0298550U (it) *	1989-01-25	1990-08-06
GB8903328D0 (en) *	1989-02-14	1989-04-05	Ethical Pharma Ltd	Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5271944A (en) *	1991-04-05	1993-12-21	Biofor, Ltd.	Pharmacologically enhanced formulations
DE4130173A1 (de) *	1991-09-11	1993-03-18	Bayer Ag	Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
GB9200607D0 (en) *	1992-01-13	1992-03-11	Ethical Pharma Ltd	Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en)	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en)	1993-09-09	2004-04-27	Penwest Pharmaceuticals Co.	Sustained release heterodisperse hydrogel systems for insoluble drugs
US5543099A (en) *	1994-09-29	1996-08-06	Hallmark Pharmaceutical, Inc.	Process to manufacture micronized nifedipine granules for sustained release medicaments
ES2168351T3 (es) *	1994-12-29	2002-06-16	Shire Deutschland Gmbh & Co Kg	Preparaciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion.
JP3220373B2 (ja)	1995-11-28	2001-10-22	バイエル薬品株式会社	持続性ニフエジピン製剤
AU695734B2 (en)	1996-07-08	1998-08-20	Penwest Pharmaceuticals Co.	Sustained release matrix for high-dose insoluble drugs
IT1284604B1 (it) *	1996-09-27	1998-05-21	Roberto Valducci	Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
US6056977A (en)	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
DE60038536T2 (de)	1999-09-30	2009-06-10	Penwest Pharmaceuticals Co.	Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
MX2007000911A (es)	2004-07-30	2007-04-12	Torrent Pharmaceuticals Ltd	Nevibolol y sus sales farmaceuticamente aceptables, proceso para su preparacion y composiciones farmaceuticas de nevibolol.
DE102004062475A1 (de) *	2004-12-24	2006-07-06	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3330727A (en) *	1960-04-19	1967-07-11	Glaxo Lab Ltd	Griseofulvin with high specific surface area
US3401221A (en) *	1964-08-25	1968-09-10	Norwich Pharma Co	Treatment of urinary tract infection
DE2348334C2 (de) *	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
DE2400819C2 (de) *	1974-01-09	1982-04-22	Bayer Ag, 5090 Leverkusen	Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
GB1579818A (en) *	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
JPS55129221A (en) *	1979-03-29	1980-10-06	Kaken Pharmaceut Co Ltd	Preparation of oral preparation containing hardly soluble medicine
CA1146866A (en) *	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material

1980
- 1980-09-09 DE DE19803033919 patent/DE3033919A1/de not_active Ceased
- 1980-12-27 JP JP55185148A patent/JPS5914446B2/ja not_active Expired
1981
- 1981-08-25 NO NO812879A patent/NO157368B/no unknown
- 1981-08-28 DE DE8181106729T patent/DE3161838D1/de not_active Expired
- 1981-08-28 EP EP81106729A patent/EP0047899B2/de not_active Expired - Lifetime
- 1981-08-28 AT AT81106729T patent/ATE5761T1/de not_active IP Right Cessation
- 1981-08-31 PH PH26121A patent/PH24097A/en unknown
- 1981-08-31 PT PT73603A patent/PT73603B/pt unknown
- 1981-09-01 DD DD81232939A patent/DD201974A5/de not_active IP Right Cessation
- 1981-09-07 NZ NZ198285A patent/NZ198285A/en unknown
- 1981-09-07 FI FI812758A patent/FI72648B/fi not_active Application Discontinuation
- 1981-09-07 GR GR65968A patent/GR78237B/el unknown
- 1981-09-07 IL IL63749A patent/IL63749A/xx not_active IP Right Cessation
- 1981-09-08 ZA ZA816213A patent/ZA816213B/xx unknown
- 1981-09-08 IE IE2075/81A patent/IE51549B1/en not_active IP Right Cessation
- 1981-09-08 CA CA000385365A patent/CA1180277A/en not_active Expired
- 1981-09-08 PL PL23295181A patent/PL232951A1/xx unknown
- 1981-09-08 AR AR286686A patent/AR226377A1/es active
- 1981-09-08 DK DK396381A patent/DK154326C/da not_active IP Right Cessation
- 1981-09-08 AU AU75063/81A patent/AU558331B2/en not_active Expired
- 1981-09-09 HU HU812594A patent/HU184879B/hu unknown

Also Published As

Publication number	Publication date
JPS5750913A (en)	1982-03-25
FI72648B (fi)	1987-03-31
ZA816213B (en)	1982-09-29
AU7506381A (en)	1982-03-18
IE51549B1 (en)	1987-01-07
PH24097A (en)	1990-03-05
HU184879B (en)	1984-10-29
EP0047899B2 (de)	1996-02-28
ATE5761T1 (de)	1984-01-15
EP0047899A1 (de)	1982-03-24
GR78237B (it)	1984-09-26
IL63749A0 (en)	1981-12-31
FI812758L (fi)	1982-03-10
AU558331B2 (en)	1987-01-29
DE3161838D1 (en)	1984-02-09
PT73603A (en)	1981-09-01
DK396381A (da)	1982-03-10
IE812075L (en)	1982-03-09
DE3033919A1 (de)	1982-04-22
NO812879L (no)	1982-03-10
JPS5914446B2 (ja)	1984-04-04
EP0047899B1 (de)	1984-01-04
CA1180277A (en)	1985-01-02
IL63749A (en)	1984-06-29
PT73603B (en)	1982-11-10
DK154326C (da)	1995-03-13
PL232951A1 (it)	1982-10-11
NZ198285A (en)	1984-04-27
DK154326B (da)	1988-11-07
AR226377A1 (es)	1982-06-30
NO157368B (no)	1987-11-30

Legal Events

Date	Code	Title	Description
1994-01-27	PV	Patent disclaimer (addendum to changes before extension act)

Publication	Publication Date	Title
EP0047899B1 (de)	1984-01-04	Feste Arzneizubereitungen enthaltend Nifedipin und Verfahren zu ihrer Herstellung
EP0126379B1 (de)	1989-04-19	Zweiphasenformulierung
DE3636123C2 (it)	1989-06-01
DE69013296T3 (de)	2000-11-09	Einzeldosen mit verzögerter Arzneistofffreigabe.
DE60118008T2 (de)	2006-10-26	Pharmazeutische zusammensetzungen mit amlodipinmaleat
DE19541128C2 (de)	1997-11-27	Stabilisierte schilddrüsenhormonhaltige Arzneimittel
DE2822882A1 (de)	1978-12-21	Nifedipine-enthaltende feste praeparatzusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
DE3915347A1 (de)	1989-11-16	Harzadsorbat und verfahren zu seiner herstellung
DE2224534B2 (de)	1977-10-20	Pharmazeutisches praeparat mit langsamer wirkstoffabgabe
DE3720757A1 (de)	1989-01-05	Dhp-manteltablette
DD285720A5 (de)	1991-01-03	Verfahren zur herstellung einer saeurebindenden, aufschaeumenden zubereitung
DE69814850T2 (de)	2004-03-11	Paracetamol enthaltende schlickbare tablette
EP0607775A2 (de)	1994-07-27	Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DE3212736A1 (de)	1983-10-13	Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung
DE69100954T2 (de)	1994-05-05	Lagerstabile orale Glucosaminsulfat-Dosisformen und Verfahren zu deren Herstellung.
DE3419131A1 (de)	1985-11-28	Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
EP0531845B1 (de)	1996-08-07	Pharmazeutische Zubereitungen mit einer speziellen Kristallmodifikation des 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsäure-isopropyl-(2-methoxyethyl)-esters
DE69103724T2 (de)	1995-04-06	Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
DE3419130A1 (de)	1985-11-28	Nifedipinkombinationspraeparate und verfahren zu ihrer herstellung
DE3639073A1 (de)	1988-05-26	Feste arzneizubereitungen und verfahren zu ihrer herstellung
DE2629200A1 (de)	1977-02-03	Oral verabfolgbares festes antidepressionsmittel und dessen herstellung
DE2532180C2 (de)	1986-12-18	Verwendung von Etozolin bei der Bekämpfung der Hypertonie
EP0800392B1 (de)	2002-02-06	Pharmazeutische zubereitungen, enthaltend nifedipin und verfahren zu ihrer herstellung
EP0253293A1 (de)	1988-01-20	Neue Guanidiniumasparaginate
DE4023136A1 (de)	1991-02-14	Neue galenische, orale form zur verbesserung der bioverfuegbarkeit von medikamenten